ArticleCancer management and research2025
Effectiveness of Palliative Chemotherapy and Associated Prognostic Factors in Advanced Small Bowel Adenocarcinoma: A Propensity Score-Matched Analysis.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy with limited evidence guiding systemic treatment in the advanced stages. This study evaluated the effectiveness of palliative chemotherapy and revealed the prognostic factors associated with survival in patients with metastatic or unresectable SBA. Patients and Methods: We conducted a retrospective cohort study of patients diagnosed with advanced SBA at a single tertiary center in Thailand between 2005 and 2024. The patients were treated with palliative systemic chemotherapy or best supportive care (BSC). Survival outcomes were assessed using Kaplan-Meier estimates and Cox regression analyses. Propensity score-matching (PSM) was performed to adjust for baseline imbalances. Results: This study included 106 patients; of these, 39 (36.8%) received palliative chemotherapy. After 1:1 PSM, 39 matched pairs were analyzed. Chemotherapy significantly improved overall survival (OS) compared with that of the BSC, with a median OS of 10.4 vs 2.6 months (hazard ratio 0.36; 95% confidence intervals 0.22-0.59; Conclusion: Palliative chemotherapy significantly prolongs survival in patients with advanced SBA compared with that of BSC, particularly in those with a good performance status. Doublet fluoropyrimidine-based regimens offered superior outcomes. These findings support the use of systemic chemotherapy for this rare malignancy, highlighting the significance of patient selection and performance status in guiding treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.